Latest News & Updates
Breaking News
3 hours ago
Simantini Singh Deo
Other trending news you may like to read
Mesoblast Reaches Key Milestone in Phase 3 Trial of Rexlemestrocel-L for Chronic Back Pain
Mesoblast hits 300-patient enrollment target in its Phase 3 MSB-DR004 trial of rexlemestrocel-L for chronic low back pain, with top-line results and BLA submission targeted for mid-2027.
Simantini Singh Deo
MBX Biosciences Appoints Steve Hoerter As CEO And Chairman, Names John Smither CFO
MBX Biosciences names Steve Hoerter as CEO and John Smither as CFO as it targets three H2 2026 milestones including a Phase 3 trial for canvuparatide in chronic hypoparathyroidism.
Simantini Singh Deo
Silo Pharma's QwikAgents Joins AMD AI Developer Program To Accelerate AI Platform Development
Silo Pharma's AI subsidiary QwikAgents joins AMD's AI Developer Program to accelerate development of its AI agent platform for enterprises and individual users, with plans starting at $14/month.
Simantini Singh Deo
Celcuity Receives FDA Approval For REVTORPYK To Treat Advanced HR+/HER2- Breast Cancer
Celcuity receives FDA approval for REVTORPYK (gedatolisib) to treat HR+/HER2-negative, PIK3CA wild-type advanced or metastatic breast cancer, following progression after endocrine therapy.
Simantini Singh Deo
